ArticleBiomarker research2024

Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes.

Xingcheng Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.